Bridging fibrosis

Bridging fibrosis is a pathological condition characterized by the formation of fibrous tissue bridges between portal tracts and central veins in the liver. This condition is often associated with chronic liver diseases such as hepatitis C and alcoholic liver disease.

Pathogenesis[edit | edit source]

The pathogenesis of bridging fibrosis is complex and involves several cellular and molecular mechanisms. It is primarily driven by chronic inflammation, which leads to the activation of hepatocytes and stellate cells. These activated cells produce excessive amounts of extracellular matrix proteins, leading to the formation of fibrous tissue.

Clinical Significance[edit | edit source]

Bridging fibrosis is a significant predictor of progression to cirrhosis, a severe form of liver disease characterized by extensive fibrosis and the formation of regenerative nodules. Patients with bridging fibrosis often present with symptoms of chronic liver disease, such as fatigue, weight loss, and jaundice.

Diagnosis[edit | edit source]

The diagnosis of bridging fibrosis is typically made based on liver biopsy findings. However, non-invasive methods such as elastography and serum biomarkers are increasingly being used to assess the degree of liver fibrosis.

Treatment[edit | edit source]

The treatment of bridging fibrosis primarily involves managing the underlying cause of liver disease. This may include antiviral therapy for hepatitis C, abstinence from alcohol in alcoholic liver disease, and lifestyle modifications in non-alcoholic fatty liver disease. In severe cases, liver transplantation may be required.